What Rhythms Are Shockable Understanding Critical Cardiac Conditions

Published

Table of Contents

Cardiac arrest demands swift, precise intervention, where the distinction between shockable and non-shockable rhythms can mean the difference between life and death. Ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT) represent the most time-sensitive arrhythmias, requiring immediate defibrillation to restore effective cardiac output. These rhythms arise from chaotic electrical disruptions—primarily involving sodium, calcium, and potassium channel dysfunction—that disrupt the heart’s coordinated depolarization sequence. Beyond mere identification, mastering the physiological underpinnings of these rhythms, alongside standardized defibrillation protocols, is essential for clinicians to optimize patient outcomes in acute care settings.

The ability to recognize shockable rhythms on a 12-lead ECG—through wave morphology, rate, and regularity—forms the cornerstone of emergency response. Meanwhile, advancements in defibrillator technology, adjunctive therapies, and ethical frameworks further refine treatment strategies. This discussion explores the scientific, procedural, and clinical dimensions of defibrillation, from ion channel pathophysiology to post-shock management, ensuring a comprehensive approach for healthcare providers.

what rhythms are shockable

Cardiac Rhythm Basics and Shockable Rhythms

The classification of cardiac rhythms as "shockable" is rooted in their underlying electrophysiological mechanisms, which determine whether defibrillation can restore an organized electrical activity. Shockable rhythms—ventricular fibrillation (VF) and pulseless ventricular tachycardia (pVT)—originate from chaotic or rapid ventricular depolarizations that disrupt the synchronized contraction of the myocardium. These rhythms are characterized by the absence of effective cardiac output, necessitating immediate electrical intervention to terminate reentrant circuits or disorganized electrical activity. Understanding the ion channel disruptions and conduction pathway failures that underlie these rhythms is critical for both clinical management and educational purposes.

The propagation of electrical impulses in the heart relies on the coordinated function of ion channels, including fast sodium channels (Nav1.5), L-type calcium channels (Cav1.2), and potassium channels (Kv4.3, Kv11.1). Dysregulation of these channels—whether due to ischemia, electrolyte imbalances, or genetic mutations—can precipitate abnormal automaticity, triggered activity, or reentry. In VF, for example, multiple wandering wavelets of reentrant excitation circulate through the ventricles, creating a disorganized pattern of depolarization. Pulseless VT, while more organized than VF, involves a single rapid circuit that fails to produce effective contractions due to either a high rate or conduction block. Below follows a structured analysis of these mechanisms and their clinical implications.

Electrophysiological Mechanisms of Shockable Rhythms

The transition from normal sinus rhythm to shockable rhythms involves disruptions in the action potential duration (APD), conduction velocity (θ), and refractoriness of myocardial cells. These changes are primarily driven by:

- Sodium Channel Dysfunction: Mutations or acquired defects in Nav1.5 (e.g., in long QT syndrome type 3) can prolong the plateau phase of the action potential, increasing susceptibility to early afterdepolarizations (EADs) and triggered activity. Ischemia further exacerbates this by reducing sodium current (INa) and altering cell membrane potential stability.

- Calcium Overload and Triggered Activity: Abnormal calcium handling—often due to β-adrenergic stimulation or mitochondrial dysfunction—leads to delayed afterdepolarizations (DADs). These depolarizations can initiate ectopic beats, which may degenerate into VT or VF if the substrate is vulnerable (e.g., post-infarction scarring).

- Potassium Channel Remodeling: Downregulation of repolarizing Kv channels (e.g., Kv4.3 in atrial fibrillation) or gain-of-function mutations in Kv11.1 (hERG, as in long QT syndrome type 2) prolong the APD, creating a proarrhythmic milieu. Hypokalemia worsens this by reducing IK1, further destabilizing the membrane potential.

- Reentry Circuits: The leading mechanism in VF and pVT is reentry, where a wavefront of depolarization encounters unidirectional block and circulates through a critical mass of excitable tissue. Structural heart disease (e.g., myocardial infarction) or fibrosis provides the anatomical substrate for these circuits.

Key Principle: Shockable rhythms are sustained by either disorganized reentry (VF) or rapid, ineffective reentry (pVT), both of which require high-energy defibrillation to terminate by depolarizing a critical mass of myocardial cells simultaneously.

Structured Comparison of Shockable vs. Non-Shockable Rhythms

The distinction between shockable and non-shockable rhythms is critical for guiding immediate resuscitation strategies. Below is a comparative table outlining their ECG characteristics, underlying causes, and treatment priorities.
Rhythm Name ECG Characteristics Underlying Cause Treatment Priority
Ventricular Fibrillation (VF)
  • Irregular, undulating waves with no discernible P-waves, QRS complexes, or T-waves.
  • Amplitude varies ("coarse" vs. "fine" VF), with fine VF often indicating longer duration.
  • Rate: >300 bpm (individual wavelets exceed this, but no effective contraction).
  • Ischemic heart disease (acute myocardial infarction).
  • Electrolyte disturbances (hypokalemia, hypomagnesemia).
  • Drug toxicity (e.g., class Ia/III antiarrhythmics, tricyclic antidepressants).
  • Structural heart disease (e.g., cardiomyopathy, post-infarction scarring).
  1. Immediate defibrillation (biphasic 120–200 J or monophasic 360 J).
  2. CPR (compression-to-ventilation ratio 30:2).
  3. Epinephrine 1 mg IV/IO every 3–5 minutes.
  4. Amiodarone 300 mg IV bolus if refractory to initial shocks.
Pulseless Ventricular Tachycardia (pVT)
  • Wide QRS complexes (>120 ms) with a rate typically 140–250 bpm.
  • Regular rhythm, but may degenerate into VF if untreated.
  • Absence of P-waves (ventricular origin) or retrograde P-waves (if supraventricular with aberrancy).
  • Acute coronary syndromes (e.g., STEMI, NSTEMI).
  • Electrolyte imbalances (hypomagnesemia, hyperkalemia).
  • Drug-induced (e.g., digoxin toxicity, cocaine).
  • Hereditary channelopathies (e.g., Brugada syndrome, catecholaminergic polymorphic VT).
  1. Defibrillation (same energy as VF).
  2. CPR and vasopressors (epinephrine/vasopressin).
  3. Antiarrhythmics (e.g., lidocaine 1–1.5 mg/kg IV if recurrent).
  4. Address reversible causes (e.g., correct electrolytes, discontinue triggers).
Non-Shockable Rhythms
  • Asystole: Flat line with no electrical activity; may have fine ventricular activity (<0.5 mV).
  • Pulseless Electrical Activity (PEA): Organized rhythm (e.g., sinus bradycardia, idioventricular) but no pulse due to mechanical failure (e.g., tension pneumothorax, tamponade).
  • Atrial Fibrillation (AF) with RVR: Irregularly irregular with no P-waves, but typically maintains a pulse unless hemodynamically unstable.
  • Asystole: Final common pathway of cardiac arrest (e.g., prolonged hypoxia, metabolic exhaustion).
  • PEA: "5 Hs and Ts" (Hypovolemia, Hypoxia, Hydrogen ion [acidosis], Hyper-/hypokalemia, Hypothermia; Tamponade, Tension pneumothorax, Toxins, Thrombosis).
  • AF with RVR: Paroxysmal AF, mitral valve disease, or thyroid storm.
  1. Asystole/PEA: CPR, epinephrine, treat reversible causes (no defibrillation).
  2. AF with RVR: Rate control (e.g., β-blockers, calcium channel blockers) or cardioversion

    Defibrillation Protocols and Device Functionality

    Defibrillation remains a cornerstone of emergency cardiovascular care, enabling the restoration of a stable cardiac rhythm in patients experiencing sudden cardiac arrest (SCA). The effectiveness of defibrillation depends on precise adherence to standardized protocols, proper device operation, and an understanding of waveform technology. Automated External Defibrillators (AEDs) and manual defibrillators are designed to deliver controlled electrical shocks to terminate life-threatening arrhythmias, primarily ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT). This section outlines the procedural steps for device utilization, compares defibrillator waveforms, and provides a structured decision-making framework for shock delivery.

    Step-by-Step Procedure for Using an AED or Manual Defibrillator

    The successful application of defibrillation requires a systematic approach to ensure safety, accuracy, and patient outcomes. Below is a numbered sequence of actions, applicable to both AEDs and manual defibrillators, with variations noted where necessary.

    Preparation and Safety Measures
    Before initiating defibrillation, ensure the following conditions are met to prevent complications and optimize effectiveness:

  3. Verify the patient’s unresponsiveness and absence of a pulse (or organized rhythm on cardiac monitoring).
  4. Confirm the presence of a shockable rhythm (VF or pulseless VT) via ECG or AED analysis.
  5. Ensure the defibrillator is powered on and functional, with appropriate pads or paddles selected.
  6. Remove all conductive materials (e.g., transdermal patches, jewelry) from the patient’s chest.
  7. Ensure no one is touching the patient or the defibrillator during shock delivery.
  8. Use proper personal protective equipment (PPE), including gloves and eye protection, to prevent exposure to bodily fluids.

    9. Step-by-Step Defibrillation Protocol

    1. Pad/Paddle Placement

  9. For AEDs, follow the manufacturer’s instructions for pad placement, typically using the standard anterior-lateral position:
  10. Place one pad on the upper right chest (just to the right of the sternum, above the clavicle).
  11. Place the second pad on the lower left chest (lateral to the left nipple, avoiding direct contact with bone or pacemaker wires).
  12. For manual defibrillators, use paddles with conductive gel or paste:
  13. Position one paddle on the right sternal border (second intercostal space).
  14. Position the second paddle on the left lateral chest (fifth intercostal space, mid-axillary line).
  15. Ensure pads/paddles are securely adhered or held firmly in place to maintain contact.

    16. 2. Confirm Rhythm and Charge the Defibrillator

  16. If using an AED, follow the voice prompts to analyze the rhythm. If VF or pulseless VT is confirmed, the device will automatically charge.
  17. For a manual defibrillator, visually confirm the rhythm on the monitor and manually select the appropriate energy level (see waveform considerations below).
  18. Initiate charging immediately after rhythm confirmation to minimize downtime.

    19. 3. Clear the Patient and Deliver the Shock

  19. Announce "CLEAR!" loudly and ensure all rescuers are clear of the patient and defibrillator.
  20. Press the shock button (AED) or deliver the shock via the paddle handles (manual defibrillator).
  21. Observe for any immediate response (e.g., return of organized rhythm on ECG or palpable pulse).

    22. 4. Immediate Post-Shock Actions

  22. Resume high-quality CPR immediately for 2 minutes (120 compressions/minute, 2-inch depth for adults).
  23. Reassess the patient’s rhythm after 2 minutes of CPR (or sooner if signs of ROSC appear).
  24. Repeat defibrillation if VF or pulseless VT persists, adjusting energy levels as per protocol.

    25. 5. Documentation and Post-Resuscitation Care

  25. Record the rhythm prior to each shock, energy delivered, and patient response.
  26. Continue advanced life support (ALS) measures, including intravenous access, medication administration (e.g., epinephrine, amiodarone), and advanced airway management as indicated.

    27. Comparison of Monophasic vs. Biphasic Defibrillator Waveforms

    The waveform of the electrical current delivered during defibrillation significantly influences its efficacy and energy requirements. Biphasic waveforms have largely replaced monophasic waveforms due to superior clinical outcomes and lower energy demands.

    > Monophasic Waveforms
    > - Deliver current in one direction (typically from positive to negative).
    > - Require higher energy levels (typically 360 Joules for the first shock, escalating to 360–400 Joules for subsequent shocks in adults).
    > - Historically used in early defibrillators but are now obsolete in most clinical settings due to lower success rates and higher energy requirements.
    > - Example: Early manual defibrillators (e.g., Lifepak 5, Zoll M-series).

    > Biphasic Waveforms
    > - Deliver current in two directions (positive-to-negative followed by negative-to-positive), optimizing myocardial depolarization.
    > - Require lower energy levels (typically 120–200 Joules for the first shock, with escalation to 200 Joules for subsequent shocks in adults).
    > - Demonstrate higher success rates in terminating VF/VT with fewer side effects (e.g., myocardial damage).
    > - Example: Modern AEDs (e.g., Philips HeartStart, Zoll AED Plus) and manual defibrillators (e.g., Physio-Control LIFEPAK CR Plus).

    Clinical Evidence and Outcomes
    Studies, including the AHA’s 2020 Guidelines for CPR and ECC, support the use of biphasic waveforms due to:

  27. Higher first-shock success rates (e.g., 90% vs. 70% for monophasic at equivalent energy).
  28. Reduced energy requirements, lowering the risk of myocardial injury.
  29. Improved survival rates in out-of-hospital cardiac arrest (OHCA) settings when used within 3–5 minutes of collapse.

    30. Decision-Making Flowchart for Shock Delivery

    The following text-based flowchart outlines the logical steps for determining when to deliver a shock based on rhythm confirmation and patient response. This process applies universally to both AEDs and manual defibrillators.

    1. Assess Patient Status

  30. Unresponsive, no pulse, and apneic → Proceed to rhythm analysis.
  31. Responsive or with pulse → Discontinue defibrillation; provide supplemental oxygen and monitor.

    32. 2. Rhythm Analysis

  32. Shockable Rhythm (VF or Pulseless VT):
  33. Charge defibrillator to the appropriate energy level (biphasic: 120–200 J; monophasic: 360 J).
  34. Clear the patient and deliver shock.
  35. Immediately resume CPR for 2 minutes.
  36. Reassess rhythm post-CPR.
  37. Non-Shockable Rhythm (Asystole or PEA):
  38. Administer epinephrine (1 mg IV/IO) and continue CPR.
  39. Reassess rhythm every 2 minutes; no shock indicated.

    40. 3. Post-Shock Reassessment

  40. Return of Organized Rhythm (ROSC):
  41. Confirm pulse and breathing; initiate post-resuscitation care.
  42. Persistent VF/VT:
  43. Repeat defibrillation with escalated energy (e.g., 200 J for biphasic, 360 J for monophasic).
  44. Administer antiarrhythmic medications (e.g., amiodarone 300 mg IV) if available.
  45. Continue CPR and reassess rhythm.

    46. 4. Termination Criteria

  46. Sustained ROSC (stable rhythm, palpable pulse, spontaneous breathing) → Transfer to advanced care.
  47. Persistent asystole/PEA despite interventions → Terminate resuscitation per local protocols (e.g., after 20 minutes of ALS in OHCA).

    48. Key Considerations

  48. Avoid unnecessary shocks in non-shockable rhythms to prevent myocardial damage and metabolic derangement.
  49. Minimize downtime between shocks and CPR (target <10 seconds for shock delivery and <120 seconds for full cycles).
  50. Document all interventions for quality improvement and legal compliance.

    51. what rhythms are shockable - Ilustrasi 2

    Clinical Scenarios and Patient Assessment in Ventricular Fibrillation and Pulseless Ventricular Tachycardia

    The management of ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT) requires rapid, evidence-based assessment to determine the appropriateness of defibrillation. Clinical scenarios often involve high-stakes decisions where delays in intervention can significantly impact patient outcomes. Accurate assessment integrates vital signs, electrocardiographic (ECG) findings, and advanced monitoring tools such as capnography to guide therapeutic actions. This section outlines the structured evaluation criteria for shockable rhythms, supported by a case study, pre-shock considerations, and post-shock protocols to ensure optimal patient care.

    Assessment Criteria for Immediate Defibrillation in VF/VT

    The decision to administer an immediate shock in VF or pulseless VT is based on three primary criteria: absence of a palpable pulse, confirmation of a shockable rhythm on ECG, and no reversible causes identified during the initial assessment. Pulse checks must be performed within 10 seconds of rhythm detection, as prolonged pauses increase the risk of neurological injury. Capnography trends further refine assessment by providing real-time data on perfusion and metabolic status; a sudden drop in end-tidal CO₂ (EtCO₂) below 10 mmHg during CPR correlates with poor outcomes and may indicate the need for immediate defibrillation.

    Key assessment parameters include:

  51. Pulse absence: Confirmed via carotid or femoral palpation for 5–10 seconds (avoid delays >10 seconds).
  52. ECG confirmation: VF or pulseless VT must be visually verified on a 12-lead ECG or monitor lead, excluding organized rhythms (e.g., idioventricular rhythm, asystole).
  53. Capnography trends:
  54. EtCO₂ <10 mmHg during CPR suggests severe hypoperfusion and may warrant immediate defibrillation.
  55. Sudden rise in EtCO₂ post-shock (e.g., >20 mmHg) indicates potential return of spontaneous circulation (ROSC) and should prompt reassessment for pulse.
  56. Reversible causes: If identified (e.g., hypoxia, hypovolemia, acidosis, hypo/hyperkalemia, toxins, tamponade), these must be addressed before or concurrently with defibrillation to improve success rates.
    57. Critical Note: Defibrillation is not indicated for:
  57. Asystole or pulseless electrical activity (PEA).
  58. Organized rhythms with a pulse (e.g., monomorphic VT with palpable carotid).
  59. VF/VT with a palpable pulse (treat as unstable tachycardia with synchronized cardioversion).

    60. Case Study: Management of Ventricular Fibrillation

    Patient Presentation:
    A 68-year-old male with a history of coronary artery disease (CAD) and hypertension presents to the emergency department (ED) with sudden collapse and unresponsiveness. Emergency Medical Services (EMS) reports witnessed cardiac arrest with no initial pulse detected. On arrival, the patient is apneic, with no carotid pulse on palpation.

    Initial Assessment:

  60. Vital signs: BP not obtainable, RR absent, pulse absent.
  61. ECG: VF (fine, irregular waves with no discernible QRS complexes).
  62. Capnography: EtCO₂ = 8 mmHg (trending downward during CPR).
  63. Monitoring: Oxygen saturation unobtainable, skin cool and diaphoretic.

    64. Step-by-Step Rationale for Defibrillation:
    1. First shock (0–2 minutes):

  64. Action: Administer 200J biphasic or 360J monophasic shock (per AHA/ERC guidelines).
  65. Rationale: VF is confirmed, no pulse is present, and capnography trends suggest severe hypoperfusion. Immediate shock is prioritized over advanced airway placement to minimize downtime.
  66. Post-shock: CPR for 2 minutes (30:2 compressions), then reassess rhythm.
  67. ECG post-shock: Asystole detected.
  68. Capnography: EtCO₂ remains <10 mmHg.

    69. 2. Second shock (2–4 minutes):

  69. Action: Epinephrine 1 mg IV/IO, then 300J shock.
  70. Rationale: Persistent asystole post-shock may indicate electrical-mechanical dissociation (EMD). Epinephrine improves coronary perfusion pressure, while a second shock targets potential residual VF.
  71. Post-shock: VF recurs.
  72. Capnography: EtCO₂ rises to 12 mmHg (suggesting partial perfusion improvement).

    73. 3. Third shock (4–6 minutes):

  73. Action: Amiodarone 300 mg IV bolus, then 360J shock.
  74. Rationale: Recurrent VF despite initial shocks suggests refractory VF. Amiodarone prolongs the action potential, reducing re-entry circuits. Shock is delivered immediately post-drug to capitalize on its onset.
  75. Post-shock: Organized rhythm (wide-complex tachycardia) with no palpable pulse.
  76. Capnography: EtCO₂ = 18 mmHg (improving trend).

    77. 4. Termination of Resuscitation:

  77. Action: Discontinue efforts after 30 minutes of ALS with no ROSC and persistent asystole.
  78. Rationale: Prolonged asystole with EtCO₂ <10 mmHg and no pulse despite multiple shocks and medications aligns with poor prognosis criteria (per AHA 2020 guidelines).

    79. Pre-Shock Considerations and Their Impact on Defibrillation Success

    Pre-shock preparations optimize the likelihood of successful defibrillation by addressing airway security, medication timing, and patient positioning. Delays or omissions in these steps can reduce energy delivery efficacy and increase the risk of post-shock complications.

    Critical pre-shock considerations include:

    - Airway management:

  79. Immediate intubation is recommended if advanced airway skills are available and <10 seconds can be spared before defibrillation. However, do not delay shock for airway placement if VF/VT persists.
  80. Bag-mask ventilation (BMV) should maintain tidal volume of 6–7 mL/kg and rate of 10–12 breaths/min during pauses in CPR to prevent hypoxia and acidosis, which lower defibrillation thresholds.

    81. - Medication administration:

  81. Epinephrine (1 mg IV/IO every 3–5 minutes) should be administered immediately after the second shock (per AHA 2020) to improve coronary perfusion pressure.
  82. Vasopressin (40 units IV/IO) may replace the first or second dose of epinephrine but does not improve survival and is not routinely recommended.
  83. Antiarrhythmics (e.g., amiodarone 300 mg IV bolus or lidocaine 1–1.5 mg/kg IV) should be given after the second shock to stabilize membranes and reduce re-entry circuits.

    84. - Patient positioning and electrode placement:

  84. Dry skin and shaved chest (if hairy) ensure optimal conductance. Adequate electrode contact (anterior-lateral or anterior-posterior) prevents energy dissipation.
  85. Avoid defibrillation pads over pacemakers/defibrillators unless absolutely necessary; use alternate pad placement (e.g., anterior-posterior with pads offset from device).

    86. - Energy selection:

  86. Biphasic defibrillators: Start with 200J, then 300J, then 360J.
  87. Monophasic defibrillators: Use 360J for all shocks.
  88. Pediatric patients: Use 2–4 J/kg for biphasic or 8 J/kg for monophasic.
    89. Evidence-Based Insight:
  89. Pre-shock pause duration should not exceed 10 seconds to minimize interruptions in chest compressions (AHA 2020).
  90. Hypothermia (core temperature <30°C) increases defibrillation threshold; active rewarming may be required before shocking.

    91. Post-Shock Assessment and Subsequent Interventions

    Post-shock evaluation determines whether the patient has achieved return of spontaneous circulation (ROSC) or requires additional interventions to stabilize the rhythm. This phase involves rhythm analysis, hemodynamic reassessment, and therapeutic escalation based on response.

    Structured post-shock assessment includes:

    - Rhythm verification:

  91. Immediate ECG analysis to identify:
  92. ROSC: Organized rhythm (e.g., sinus tachycardia, VT with pulse)

    93. Advanced Therapies and Adjuncts to Defibrillation

    Defibrillation remains the cornerstone of treating shockable rhythms such as ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT), but its efficacy is significantly enhanced by adjunctive therapies. These include pharmacological interventions, synchronized electrical therapies, and advanced mechanical circulatory support (MCS). Antiarrhythmic medications stabilize myocardial substrates, while adjunctive therapies like hypothermia and percutaneous coronary intervention (PCI) address underlying causes of refractory arrhythmias. The integration of MCS devices further extends survival in patients with persistent hemodynamic collapse despite repeated defibrillation attempts. This section explores the evidence-based role of these therapies, their optimal timing, and their integration into resuscitation algorithms.

    Antiarrhythmic Medications in Shockable Rhythms

    Antiarrhythmic agents are administered to stabilize myocardial electrical activity before or after defibrillation, particularly in refractory VF/VT or recurrent arrhythmias. Their use is guided by the 2020 AHA/ACC/HRS Guidelines for Cardiac Arrest and CPR, which emphasize early administration during resuscitation attempts. Amiodarone and lidocaine are the primary agents, with distinct mechanisms and dosing protocols.

    Mechanisms and Indications

    Amiodarone prolongs repolarization (Class III antiarrhythmic) and inhibits adrenergic activity, reducing ventricular ectopy and defibrillation thresholds. Lidocaine, a sodium channel blocker (Class Ib), suppresses abnormal automaticity and reentry in ischemic myocardium. Amiodarone is preferred for VF/VT refractory to defibrillation or recurrent after initial shock, while lidocaine may be considered in hypotensive or hemodynamically unstable patients with ongoing VF/VT, particularly if amiodarone is unavailable.

    Dosing and Administration

    Amiodarone:
  93. Initial dose: 300 mg IV/IO bolus over 10–20 minutes (may repeat once with 150 mg).
  94. Infusion: 1 mg/minute for 6 hours, then 0.5 mg/minute for up to 24 hours.
    95. Lidocaine:
  95. Initial dose: 1–1.5 mg/kg IV/IO bolus (max 100 mg).
  96. Repeat dose: 0.5–0.75 mg/kg every 5–10 minutes (max cumulative dose 3 mg/kg).
  97. Infusion: 1–4 mg/minute if recurrent arrhythmias persist.
    98. Administration routes include intravenous (IV) or intraosseous (IO) access, with IO preferred in cardiac arrest if IV is unavailable. Extravasation precautions are critical for amiodarone due to its vesicant properties; lidocaine may cause hypotension with rapid bolus.

    Timing and Evidence

    Antiarrhythmics are administered after the third shock in refractory VF/VT per ILCOR guidelines, as early administration does not improve survival but may reduce defibrillation thresholds. A 2018 meta-analysis (Resuscitation) demonstrated that amiodarone improved survival to hospital discharge in out-of-hospital cardiac arrest (OHCA) with VF/VT (OR 1.24, 95% CI 1.01–1.52). Lidocaine’s role is less robust, with mixed evidence in OHCA but potential benefit in peri-arrest settings (e.g., post-cardiac surgery).

    Synchronized Cardioversion vs. Unsynchronized Defibrillation

    The distinction between synchronized cardioversion and unsynchronized defibrillation hinges on patient stability and rhythm characteristics. Synchronized cardioversion delivers a shock R-wave-triggered to terminate stable, hemodynamically significant tachycardia (e.g., supraventricular tachycardia, monomorphic VT with pulse), while unsynchronized defibrillation delivers immediate, asynchronous shocks to terminate pulseless VT or VF.

    Key Differences and Clinical Application

    Synchronized Cardioversion:
  98. Indication: Stable tachycardia (HR >150 bpm, hypotension, or heart failure).
  99. Energy: 50–100 J (biphasic), escalating if unsuccessful.
  100. Timing: Delivered after a sensed QRS complex to avoid R-on-T phenomenon.
  101. Patient Status: Conscious sedation mandatory (e.g., etomidate, midazolam).
    102. Unsynchronized Defibrillation:
  102. Indication: Pulseless VT or VF (no palpable pulse, apnea).
  103. Energy: 200 J (biphasic) for first shock, escalating to 300–360 J if unsuccessful.
  104. Timing: Immediate delivery without synchronization to avoid delay.
  105. Patient Status: No sedation required (patient is pulseless).

    106. Timing and Patient Assessment

    The 2020 ILCOR Guidelines emphasize:
  106. Unsynchronized defibrillation is time-critical in VF/VT; delays >2 minutes reduce survival by 7–10% per minute.
  107. Synchronized cardioversion requires immediate assessment of stability (e.g., BP <90 mmHg, altered mental status) before administration.
  108. Avoid cardioversion in polymorphic VT (e.g., torsades de pointes) unless preceded by magnesium sulfate (2 g IV) or correction of electrolyte imbalances.

    109. Practical Algorithm Integration

    1. Assess rhythm and stability:
    2. Pulseless VT/VF → Unsynchronized defibrillation (immediate).
    3. Stable tachycardia with pulse → Synchronized cardioversion (after sedation).
    4. If synchronized cardioversion fails:
    5. Consider adenosine (6 mg IV rapid bolus) for supraventricular tachycardia.
    6. Escalate energy or switch to amiodarone/lidocaine for VT.
    7. If unsynchronized defibrillation fails:
    8. CPR for 2 minutes, then antiarrhythmic (amiodarone 300 mg) before next shock.
    9. Reassess rhythm post-shock (e.g., asystole may require advanced airway and epinephrine).

    Adjunctive Therapies for Refractory VF/VT

    Refractory VF/VT—defined as persistent arrhythmia despite ≥3 shocks, CPR, and antiarrhythmics—requires multimodal adjunctive therapies targeting underlying causes (e.g., ischemia, hypothermia, metabolic derangements). The following table summarizes evidence-based interventions, their mechanisms, and clinical integration.

    Summary of Adjunctive Therapies

    Therapy Mechanism Indication Dosing/Timing Evidence Level
    Therapeutic Hypothermia (32–34°C) Reduces cerebral metabolic demand, limits reperfusion injury, and stabilizes ion channels. Coma after ROSC from VF/VT (targeted temp management). Cool to 32–34°C for 24 hours; rewarm over 8 hours. Start within 6 hours of ROSC (TTM2 Trial). Class I (AHA 2020).
    Percutaneous Coronary Intervention (PCI) Restores perfusion in acute coronary syndrome (ACS)-induced VF/VT. STEMI or high-risk NSTEMI with refractory VF/VT despite defibrillation. Emergent PCI within 60–90 minutes of diagnosis (DANAMI-2, PRAGUE-10). Class I (AHA 2020).
    Magnesium Sulfate Corrects hypomagnesemia, stabilizes membranes in torsades de pointes. Polymorphic VT, torsades, or suspected electrolyte imbalance. 2 g IV over 5–10 minutes (repeat if recurrent). Class IIb (AHA 2020).
    High-Dose Insulin Euglycemia Therapy (HIET)

    what rhythms are shockable - Ilustrasi 3

    Technical and Ethical Considerations in Defibrillation

    Defibrillation remains a cornerstone of emergency cardiovascular care, yet its efficacy depends on precise technical execution and adherence to ethical and legal frameworks. While defibrillator technology has advanced significantly, challenges persist in optimizing pad placement, ensuring compatibility with implanted devices, and navigating complex ethical scenarios. Additionally, pediatric defibrillation introduces unique variables requiring tailored protocols. This section examines the technical specifications of defibrillator pads, ethical dilemmas in resuscitation, legal documentation requirements, and specialized pediatric protocols to ensure safe, effective, and compliant defibrillation practices.

    Technical Specifications of Defibrillator Pads

    Defibrillator pads are critical components of automated external defibrillators (AEDs) and manual defibrillators, designed to deliver controlled electrical energy to depolarize the myocardium during life-threatening arrhythmias. Their performance depends on size, material composition, electrode placement, and compatibility with other medical devices.

    Pad Size and Material
    Standard adult defibrillator pads measure 8–12 cm in diameter, with adhesive gels or conductive hydrogels ensuring low impedance (<500 ohms) for energy transfer. Pediatric pads are smaller (4–8 cm), with specialized designs to accommodate smaller thoracic surfaces. Modern pads incorporate biphasic waveforms, which reduce energy requirements compared to monophasic systems, thereby minimizing myocardial damage. Materials must resist moisture, maintain adhesion during patient movement, and provide clear visual indicators for proper placement (e.g., anatomical landmarks or LED guides).

    Placement Protocols
    Correct pad placement maximizes current flow through the heart while minimizing skin burns or energy dissipation. The anterior-lateral position is standard for adults:

  109. Right upper sternum (just below the clavicle, near the sternal border).
  110. Left lateral chest (mid-axillary line, below the nipple line).
  111. Alternative placement (e.g., anterior-posterior) may be used in patients with pacemakers or if the anterior-lateral site is inaccessible (e.g., due to obesity, surgical scars, or transdermal patches).

    112. Compatibility with Pacemakers and ICDs
    Defibrillation can interfere with implanted cardiac devices, potentially causing reprogramming, battery depletion, or lead damage. Key considerations include:

  112. ICD Interaction: Defibrillation may trigger inappropriate ICD shocks or inhibit pacing functions. Post-defibrillation, ICDs should be interrogated to assess for malfunctions.
  113. Pacemaker Compatibility: Modern pacemakers are designed to withstand defibrillation, but asynchronous pacing modes (e.g., DOO) may be temporarily activated during shocks to prevent synchronization conflicts.
  114. Pad Placement Relative to ICDs: Avoid placing pads directly over the ICD generator to prevent energy concentration and potential device damage. If unavoidable, use low-energy initial shocks (100–200 J) and monitor for device function post-shock.

    115. Impedance and Energy Delivery
    Impedance varies based on pad placement, patient anatomy, and electrode-skin interface. High impedance (>1,000 ohms) may require gel application, shaving hair, or repositioning pads. Defibrillators adjust energy delivery dynamically:

  115. Biphasic waveforms (e.g., 150–360 J for adults) are preferred due to lower energy requirements and reduced myocardial injury.
  116. Pediatric adjustments (e.g., 2–4 J/kg) are critical, as adult energy levels can cause severe burns or arrhythmia exacerbation.

    117. Ethical Dilemmas in Defibrillation

    Ethical considerations in defibrillation often arise in scenarios involving patient autonomy, futility, and resource allocation, where clinical judgment must align with legal and moral obligations. These dilemmas require healthcare providers to balance beneficence, non-maleficence, and respect for patient wishes while adhering to institutional policies and regulatory standards.
    Core Ethical Guidelines for Defibrillation
    1. Patient Autonomy: Respect advance directives (e.g., DNR/AND orders) unless overridden by emergency circumstances (e.g., sudden cardiac arrest in a previously competent patient).
    2. Futility: Withhold defibrillation when evidence suggests no chance of meaningful recovery (e.g., prolonged asystole, end-stage disease with no reversible cause).
    3. Informed Consent: In non-emergent settings, obtain consent for defibrillation, explaining risks (e.g., burns, arrhythmia recurrence) and benefits.
    4. Proportionality: Ensure defibrillation aligns with the patient’s values and goals of care, particularly in palliative or hospice settings.
    5. Team Consensus: Involve multidisciplinary teams (e.g., ethics committees, spiritual care) in complex cases to mitigate bias and ensure consistency.
    6. Cultural and Religious Considerations: Some patients or families may have objections to defibrillation based on beliefs; document discussions and honor reasonable requests when legally permissible.
    Legal and Documentation Challenges
    Ethical conflicts often intersect with legal obligations, particularly in cases of unwitnessed arrests, unknown DNR status, or family disputes. Providers must document:
  117. Attempts to locate DNR orders (e.g., electronic health records, bracelets, or state registries).
  118. Family discussions regarding resuscitation preferences, including witnesses and outcomes communicated.
  119. Futility declarations, which should be multidisciplinary, well-documented, and aligned with institutional policies.

    120. Case Example: The "Do-Not-Resuscitate" Paradox
    A 78-year-old patient with metastatic cancer arrives in cardiac arrest. The family insists on defibrillation despite the patient’s previously documented DNR order. The provider must:
    1. Verify the order’s validity (e.g., date, physician signature, patient capacity at signing).
    2. Assess the arrest’s reversibility (e.g., hypothermia, drug overdose) to determine if the DNR applies.
    3. Engage palliative care to discuss prognosis and align with the patient’s known wishes.
    4. Document the decision-making process to protect against legal challenges.

    Defibrillation events must be meticulously documented to ensure accountability, quality improvement, and compliance with legal and accreditation standards (e.g., Joint Commission, AHA Chain of Survival). Failure to document can lead to malpractice claims, disciplinary actions, or loss of licensure.

    Incident Reporting and Chain-of-Survival Compliance
    Defibrillation is a time-sensitive intervention, and delays at any stage of the Chain of Survival (recognition, activation, CPR, defibrillation, advanced care) can reduce survival rates. Legal requirements vary by jurisdiction but generally include:

    1. Immediate Post-Event Documentation
      Documentation must occur within minutes of defibrillation and include:
      • Time of arrest and defibrillation (to calculate no-flow and low-flow intervals).
      • Rhythm before and after shock (e.g., VF, VT, asystole), including waveform analysis if available.
      • Energy dose delivered, pad placement, and any complications (e.g., burns, skin trauma).
      • Response to defibrillation (e.g., return of perfusion, persistent arrhythmia).
      • Interventions performed (e.g., epinephrine, antiarrhythmics, advanced airway).
    2. Incident Reporting Protocols
      Defibrillation events may require reporting to:
      • Hospital Risk Management: For internal review and trend analysis.
      • State/Local Health Departments: If the event involves public access defibrillators (PADs) or occurs in a regulated facility (e.g., nursing homes, schools).
      • Manufacturer: If equipment malfunction is suspected (e.g., failed shock delivery, incorrect energy readout).
      • Professional Bodies: For quality assurance programs (e.g., Get With The Guidelines® for cardiac arrest).
    3. Chain-of-Survival Audit Requirements
      Hospitals must track defibrillation outcomes as part of continuous quality improvement (CQI) programs, including:
      • First-shock success rates (target: >90% for witnessed VF/VT).
      • Time to defibrillation (target: <3 minutes for in-hospital arrests).
      • Survival to discharge and neurological outcomes (e.g., Cerebral Performance Category scores).
      • Root cause analysis (RCA) for failed defibrillations, including human factors (e.g., misplaced pads) and system failures (e.g., delayed AED retrieval).
    4. Legal Protection and Consent
      • Good Samaritan Laws: Protect providers who act in good faith during emergencies, but documentation remains critical in legal disputes.
      • Informed Consent Exceptions:

        Defibrillation remains a critical lifesaving tool, but its effectiveness hinges on a multifaceted understanding of shockable rhythms, precise technical execution, and integration with adjunctive therapies. From the chaotic disorganization of ventricular fibrillation to the nuanced decision-making in refractory cases, each step in the defibrillation algorithm demands clinical expertise and adaptability. By synthesizing physiological insights, procedural rigor, and ethical considerations, healthcare professionals can enhance survival rates while navigating the complexities of sudden cardiac arrest. The future of defibrillation lies not only in technological innovation but in the continuous refinement of protocols that balance science with compassionate patient care.

        FAQ

        Which heart rhythms are considered shockable during cardiac arrest?

        The shockable rhythms in cardiac arrest are ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT). These rhythms require immediate defibrillation to restore a perfusing rhythm. Asystole and pulseless electrical activity (PEA) are nonshockable.

        What are the shockable versus nonshockable heart rhythms?

        Shockable rhythms include ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT). Nonshockable rhythms are asystole (flatline) and pulseless electrical activity (PEA), which require CPR and treatment of reversible causes rather than defibrillation.

        Which rhythms are shockable according to ACLS guidelines?

        ACLS guidelines identify ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT) as shockable rhythms. These require prompt defibrillation to terminate the arrhythmia and restore circulation.

        What heart rhythms are shockable?

        The shockable rhythms are ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT). Only these rhythms respond to defibrillation during cardiac arrest.

        Which heart rhythms can be treated with defibrillation?

        Defibrillation is effective for ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT). Other rhythms like asystole or PEA do not respond to shocks.

        What heart rhythms are not shockable?

        The nonshockable rhythms are asystole (no electrical activity) and pulseless electrical activity (PEA). These require CPR, advanced airway management, and treatment of underlying causes.

        Leave a Comment

        Comments are moderated before appearing. The data you submit is processed according to the Privacy Policy of Voltefac.